Ongoing complete response reported in Phase 2 clinical trial of TRC105 in choriocarcinoma TRC102 advanced to Phase 2 clinical development Cash and short-term investments balance of $57.7 million at September 30, 2015 SAN DIEGO, Nov. 03, 2015 — TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced its financial results for the third quarter ended September 30, 2015.
